Teladoc Health, Inc.'s stock has declined significantly, from a high of $14 per share in February to $7 per share, with ongoing financial struggles and underperformance in key segments. The company ...

JPMorgan analyst Lisa C. Gill maintained a Neutral rating on Teladoc Health, Inc (NYSE:TDOC) on Thursday with a price target of $9, down from the prior $11. On April 30, Teladoc reported first-quarter ...

Teladoc Health faces challenges but offers long-term opportunities due to international market expansion and increased demand for chronic care services. Despite BetterHelp's losses, Teladoc's ...

Citron Research sees Teladoc as a bargain ready to rip higher, citing the end of this government shutdown as a bullish catalyst. While Citron's favorite catalyst seems questionable, Teladoc's bargain ...